CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 9th, 2023, at 8:00 a.m. ET, to report second quarter 2023 financial results and provide business updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com.
BiomX, Inc.
Anat Primovich
Corporate Project Manager
+97250-6977228
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
LifeSci Advisors, LLC
John Mullaly
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.70 |
| Daily Change: | -0.05 -6.09 |
| Daily Volume: | 219,707 |
| Market Cap: | US$12.730M |
November 14, 2024 September 18, 2024 September 03, 2024 August 15, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
